全文获取类型
收费全文 | 216125篇 |
免费 | 14747篇 |
国内免费 | 2523篇 |
专业分类
耳鼻咽喉 | 2242篇 |
儿科学 | 5071篇 |
妇产科学 | 4939篇 |
基础医学 | 28525篇 |
口腔科学 | 4605篇 |
临床医学 | 21507篇 |
内科学 | 44704篇 |
皮肤病学 | 4050篇 |
神经病学 | 18732篇 |
特种医学 | 8719篇 |
外国民族医学 | 12篇 |
外科学 | 31372篇 |
综合类 | 6091篇 |
现状与发展 | 9篇 |
一般理论 | 150篇 |
预防医学 | 14501篇 |
眼科学 | 4551篇 |
药学 | 15759篇 |
23篇 | |
中国医学 | 1923篇 |
肿瘤学 | 15910篇 |
出版年
2023年 | 1337篇 |
2022年 | 2553篇 |
2021年 | 4949篇 |
2020年 | 3248篇 |
2019年 | 4406篇 |
2018年 | 5399篇 |
2017年 | 4166篇 |
2016年 | 4600篇 |
2015年 | 5816篇 |
2014年 | 7906篇 |
2013年 | 10151篇 |
2012年 | 15257篇 |
2011年 | 15746篇 |
2010年 | 9301篇 |
2009年 | 8620篇 |
2008年 | 13676篇 |
2007年 | 14357篇 |
2006年 | 13674篇 |
2005年 | 13665篇 |
2004年 | 12783篇 |
2003年 | 12156篇 |
2002年 | 11223篇 |
2001年 | 3323篇 |
2000年 | 2721篇 |
1999年 | 2924篇 |
1998年 | 2649篇 |
1997年 | 2097篇 |
1996年 | 1833篇 |
1995年 | 1663篇 |
1994年 | 1486篇 |
1993年 | 1354篇 |
1992年 | 1479篇 |
1991年 | 1363篇 |
1990年 | 1136篇 |
1989年 | 1078篇 |
1988年 | 977篇 |
1987年 | 991篇 |
1986年 | 860篇 |
1985年 | 826篇 |
1984年 | 862篇 |
1983年 | 753篇 |
1982年 | 873篇 |
1981年 | 822篇 |
1980年 | 701篇 |
1979年 | 569篇 |
1978年 | 536篇 |
1977年 | 506篇 |
1976年 | 451篇 |
1975年 | 394篇 |
1974年 | 347篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
92.
Najat C Daw Wayne L Furman Clinton F Stewart Lisa C Iacono Mark Krailo Mark L Bernstein Janet E Dancey Rose Anne Speights Susan M Blaney James M Croop Gregory H Reaman Peter C Adamson 《Journal of clinical oncology》2005,23(25):6172-6180
PURPOSE: Epidermal growth factor receptor is expressed in pediatric malignant solid tumors. We conducted a phase I trial of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in children with refractory solid tumors. PATIENTS AND METHODS: Gefitinib (150, 300, 400, or 500 mg/m2) was administered orally to cohorts of three to six patients once daily continuously until disease progression or significant toxicity. Pharmacokinetic studies were performed during course one (day 1 through 28). RESULTS: Of the 25 enrolled patients, 19 (median age, 15 years) were fully evaluable for toxicity and received 54 courses. Dose-limiting toxicity was rash in two patients treated with 500 mg/m2 and elevated ALT and AST in one patient treated with 400 mg/m2. The maximum-tolerated dose was 400 mg/m2/d. The most frequent non-dose-limiting toxicities were grade 1 or 2 dry skin, anemia, diarrhea, nausea, and vomiting. One patient with Ewing's sarcoma had a partial response. Disease stabilized for 8 to > or = 60 weeks in two patients with Wilms' tumor and two with brainstem glioma (one exophytic). At 400 mg/m2, the median peak gefitinib plasma concentration was 2.2 microg/mL (range, 1.2 to 3.6 microg/mL) and occurred at a median of 2.3 hours (range, 2.0 to 8.3 hours) after drug administration. The median apparent clearance and median half-life were 14.8 L/h/m2 (range, 3.8 to 24.8 L/h/m2) and 11.7 hours (range, 5.6 to 22.8 hours), respectively. Gefitinib systemic exposures were comparable with those associated with antitumor activity in adults. CONCLUSION: Oral gefitinib is well tolerated in children. Development of the drug in combination with cytotoxic chemotherapy will be pursued. 相似文献
93.
94.
95.
The 55-kD bactericidal/permeability-increasing protein (BPI) is a neutrophil-derived polypeptide belonging to a family of
lipid and endotoxin binding proteins. BPI is composed of two functionally distinct structural domains: a potently antibacterial
and antiendotoxin ∼ 20-kD aminoterminal half, and an opsonic carboxy-terminal portion. In multiple animal models, a recombinant
amino-terminal fragment of BPI (rBPI21) is nontoxic and protects against gram-negative bacteria and endotoxin. In humans, rBPI21 is also nontoxic and nonimmunogenic and has undergone phase II/III clinical trials with apparent therapeutic benefit. 相似文献
96.
Further evidence of dopamine transporter dysregulation in ADHD: a controlled PET imaging study using altropane. 总被引:4,自引:0,他引:4
Thomas J Spencer Joseph Biederman Bertha K Madras Darin D Dougherty Ali A Bonab Elijahu Livni Peter C Meltzer Jessica Martin Scott Rauch Alan J Fischman 《Neuropsychopharmacology》2007,62(9):1059-1061
BACKGROUND: The dopamine transporter (DAT) is known to be a key regulator of dopamine, and recent studies of genetics, treatment, and imaging have highlighted the role of DAT in attention-deficit/hyperactivity disorder (ADHD). The findings of in vivo neuroimaging of DAT in ADHD have been somewhat discrepant, however. METHOD: Dopamine transporter binding was measured using a highly selective ligand (C-11 altropane) and positron emission tomography (PET). The sample consisted of 47 well-characterized, treatment-na?ve, nonsmoking, non-comorbid adults with and without ADHD. Additionally, control subjects had few symptoms of ADHD. RESULTS: Results showed significantly increased DAT binding in the right caudate in adults with ADHD compared with matched control subjects without this disorder. CONCLUSIONS: These results confirm abnormal DAT binding in the striatum of adults with ADHD and provide further support that dysregulation of DAT may be an important component of the pathophysiology of ADHD. 相似文献
97.
98.
Charlotte J. Harden Bernard M. Corfe J. Craig Richardson Peter W. Dettmar Jenny R. Paxman 《Nutrition Research》2009
This cross-sectional analysis evaluated the effect of age and body mass index (BMI) on Three-Factor Eating Questionnaire scores in males. Subjects (n = 60) were recruited according to BMI status. Each completed the 51-item Three-Factor Eating Questionnaire. The group was split at the median age to produce a “younger” and “older” group for statistical analysis. A 2-way between-groups analysis of variance revealed a significant main effect of BMI on disinhibition (P = .003) and hunger (P = .041) with higher levels found in overweight males compared to healthy-weight counterparts. A significant main effect of age on hunger (P = .046) demonstrated older males were less susceptible to hunger than younger males. These insights provide a better understanding of eating behavior across the male life cycle and may assist health professionals to better guide men in weight management in the light of rising overweight/obesity. 相似文献
99.
100.
BACKGROUND AND PURPOSE: Taiwan's National Health Insurance (NHI) program has considered the use of capitation payments to health care providers as a method for control of the rising costs of the system. The establishment of capitation payments usually requires the performance of risk adjustment. The purposes of this study were to develop a diagnosis-based risk adjustment model for the NHI and to evaluate its predictability. METHODS: Using a 2% random sample of 371,620 NHI enrollees, the authors developed a Taiwan version of the Principal Inpatient Diagnosis Cost Groups (TPIPDCGs) from 1996 claim records to predict an individual's expenditure in 1997. Weighted least squares regression models were built in an estimation sample (two-thirds of the study sample), and were cross-validated in a validation sample (the remaining one-third of the study sample). Predictive R2 and predictive ratios were used to evaluate the model's predictability. RESULTS: Only 7.88% of the study sample could be classified into 1 of the 16 TPIPDCGs. Combined with demographic variables, which alone could explain 3.7% of the variation in an individual's future expenditure, the risk adjustment model based on TPIPDCGs could explain 12.2% of expenditure variation. In addition, the finding that the predictive ratios of the TPIPDCG model approximated unity better than those of the demographic model in all subgroups indicates that the capitation payment as predicted by the TPIPDCG model for each subgroup would better correlate to the actual spending. CONCLUSION: Taiwan's risk-adjusted capitation model based on principal inpatient diagnoses has higher predictability on individual's future expenditure than its counterpart in the USA. This finding provides insight into not only the development of Taiwan's diagnosis-based risk adjustment models but also the necessity of modification when applying foreign-developed risk adjustment models to the NHI. 相似文献